Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Wowcher sorry for 'unacceptable' crocodile attack email

Published

on

Wowcher sorry for 'unacceptable' crocodile attack email

The firm’s marketing email appeared to reference an incident involving a toddler at a zoo.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Record defence export deal puts Australia on the radar

Published

on

Record defence export deal puts Australia on the radar

Australia has struck its largest defence export deal under a $2.5 billion agreement to provide Canada with world-leading radar technology.

Continue Reading

Business

UPS to invest $48 million in cold facilities amid GLP-1 boom

Published

on

UPS to invest $48 million in cold facilities amid GLP-1 boom

United Parcel Service (UPS) trucks are parked at a UPS drop yard on Oct. 28, 2025 in Vernon, California.

Mario Tama | Getty Images

United Parcel Service is investing $48 million in 27 temperature‑controlled facilities as the industry sees a boom in healthcare logistics, CNBC has learned exclusively.

Advertisement

The facilities, located across the Americas, Europe and Asia, are optimized for moving around shipments that need to be kept at certain temperatures. The company said the investment will help it stay ahead of a boom in medicines and pharmaceuticals — like some GLP-1s — that have to be kept at certain temperatures by improving speed and end-to-end chain of custody.

“Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world,” said Kate Gutmann, UPS’ president of international, healthcare and supply chain solutions. “This effort – and all of our work in healthcare logistics – extends from a deep understanding that we’re doing more than moving packages.”

The demand for temperature-sensitive biologics is projected to grow at an 8.3% compound annual growth rate through 2033 and reach a market value of roughly $39.1 billion, according to Growth Market Reports. Many new medicines are required to be stored at specific temperatures to maintain efficacy, UPS said, making healthcare logistics more crucial than before.

According to the World Health Organization, up to 50% of global vaccines are wasted every year, with a significant portion of that coming from cold-chain storage issues.

Advertisement

“These investments reflect our commitment to continue to align our leading end-to-end supply chain to protect innovative treatments and diagnostics, supporting better patient outcomes,” UPS Healthcare President John Bolla said in a statement.

UPS’ move comes as the industry overall has seen growing investments in the space, especially with the meteoric rise of GLP-1 drugs. Medicines like Novo Nordisk‘s Wegovy and Ozempic require strict refrigeration and temperature control during transit. A November KFF poll found that 1 in 8 Americans are taking GLP-1s.

UPS CEO Carol Tomé said on the company’s first-quarter earnings call in April that healthcare remains one of the company’s top priorities and biggest areas of growth.

“Our global healthcare portfolio has gained market share every year since 2021,” she said on the call. “And in the first quarter of this year, we generated our first $3 billion healthcare revenue quarter ever, with all three of our segments delivering year-over-year revenue growth.”

Advertisement

Tomé added that UPS is committed to continuing to “lean into that space in a meaningful way.”

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT)

Published

on

Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT)

This article was written by

I would describe myself as a barbell investor focused on two ends of the risk spectrum: relatively safe, income-generating investments on one side, and high-risk, high upside opportunities—primarily binary healthcare and biotech bets—on the other. Professionally, I work as an R&D researcher in the pharmaceutical industry. Combined with my background in economics and self-training in finance, this provides me with unique perspective when evaluating biotech companies. My research spans multiple dimensions of the sector, including platform technologies, IP and freedom-to-operate considerations, mechanistic feasibility, competitive landscapes, binary clinical trial readouts and corporate financials. As an individual investor, I place significant emphasis on valuation, risk management and capital allocation. On the income-investing side of the portfolio, I actively follow dividend paying stock picks, including preferred shares, REITs, BDCs and option-based income ETFs. The objective is to build a durable stream of cash flow that can support moonshot bets on the other side of the barbell. Through my writing on Seeking Alpha, I aim to share independent, research-driven investment ideas from both ends of this barbell approach. My goal is to combine scientific insight, fundamental analysis and risk management to encourage disciplined trading and develop well-grounded investment thesis.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of SMMT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Business

Form 4 The York Water Company For: 22 June

Published

on


Form 4 The York Water Company For: 22 June

Continue Reading

Business

The long tail of Trump’s trade agenda

Published

on

The long tail of Trump’s trade agenda

Industry experts say the latest proposals are designed to outlast court challenges, political cycles and administrations. 

Continue Reading

Business

Schwebel Baking set to shut down

Published

on

Schwebel Baking set to shut down

Longtime commercial baker to wind down operations over the summer.

Continue Reading

Business

Occidental Offers A 25% Upside At $70 Oil

Published

on

Occidental Offers A 25% Upside At $70 Oil

Occidental Offers A 25% Upside At $70 Oil

Continue Reading

Business

Amazon Prime Day expected to drive $26.3 billion in online sales

Published

on


Amazon Prime Day expected to drive $26.3 billion in online sales

Continue Reading

Business

Alan Greenspan, architect of the modern American economy, dies aged 100

Published

on

Alan Greenspan, architect of the modern American economy, dies aged 100

As chairman of the Federal Reserve, Alan Greenspan became the world’s most high-profile banker.

Continue Reading

Business

Medical Properties: Strong Recovery Potential (NYSE:MPT)

Published

on

Medical Properties Trust: High Safety Margin

This article was written by

I am interested in a lot of technology and AI stocks like Google, Nvidia, AMD, Tesla and Amazon.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MPT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Advertisement
Continue Reading

Trending

Copyright © 2025